DNA polymerase inhibitors for treating hepatitis B: a safety evaluation

References

• Schweitzer A, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015. published online July 28. DOI:10.1016/S0140-6736(15)61412-X.
   PubMed Web of Science ®Google Scholar
• Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49:S185–S195.
   Web of Science ®Google Scholar
• McKenzie R, Fried MW, Sallie R et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995;333:1099–1105.
   PubMed Web of Science ®Google Scholar
• Matthew SJ. Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther. 2007;29:2635–2653.
   PubMed Web of Science ®Google Scholar
• Yf L, Gane E, Leung N, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486–495.
   PubMed Web of Science ®Google Scholar
• Wang Y, Thongsawat S, Gane E, et al. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hep. 2013;20:e37–e46.
   PubMed Web of Science ®Google Scholar
• Ma WM, Lee XH, Liu Y, et al. Multivariate analysis of serum creatine kinase elevations during 3 years telbivudine therapy for 218 patients with chronic hepatitis B. Hepatology. 2011;54(4 Suppl):1056A.
   Google Scholar
• Boxer A, Protano M, Vachon MC, et al. Telbivudine elevations of CPK in chronic hepatitis B patients in a clinical setting. J. Hepatol. 2010;52(Suppl.4):533A.
   Google Scholar
• Zou XJ, Jiang XQ, Tian DY, et al. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. J.l Viral Hep. 2011;18:892–896.
   PubMed Web of Science ®Google Scholar
• Finsterer J, Ay L. Myotoxicity of telbivudine in pre-existing muscle damage. Virol J. 2010;7:323.
   PubMed Web of Science ®Google Scholar
• Assy N, Djibre A, Tzuker M, et al. Vitamin D supplement prevents myalgia and elevation of CPK in chronic hepatitis B patients treated with telbvudine. J. Hepatol. 2011;54:S283.
   Web of Science ®Google Scholar
• Goncalves J, Laeufle R, Avila C. Increased risk with combination of telbivudine and pegylated-interferon alfa-2a in study CLDT600A2406, compared to uncommon rate with telbivudine monotherapy from the Novartis global database. J. Hepatol. 2009;50:S329–S330.
   Web of Science ®Google Scholar
• Marcellin P, Avila C, Wursthorn K, et al. Telbivudine plus peg-interferon in HbeAg-positive chronic hepatitis B – very potent antiviral efficacy but risk of peripheral neuropathy. J. Hepatol. 2010;52:S6–7.
   Web of Science ®Google Scholar
• Marcellin P, Wursthorn K, Wedemeyer H, et al. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. J. Hepatol. 2015;62:41–47.
   PubMed Web of Science ®Google Scholar
• Fodale V, Mazzeo A, Pratico C, et al. Fatal exacerbation of peripheral neuropathy during lamivudine therapy: evidence for iatrogenic mitochondrial damage. Anaesthesia. 2005;60:806–810.
   PubMed Web of Science ®Google Scholar
• Xu HL, Wang ZX, Zheng LM, et al. Lamivudine/telbivudine associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion. J Clin Pathol. 2014;67:999–1005.
   PubMed Web of Science ®Google Scholar
• Zhang XH, Wu YK, Hong C, et al. Clinical characterization of peripheral neuropathy associated with entecavir in patients with HBV-induced cirrhosis. Hepatol Int. 2012;6:132–133.
   Web of Science ®Google Scholar
• Amet S, Bronowicki JP, Pol S, et al. Prevalence of renal abnormalities in chronic HBV infection: the HARPE study. Liver Int. 2015;35:148–155.
   PubMed Web of Science ®Google Scholar
• Mauss S, Berger F, Herrmann E, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J. Hepatol. 2011;55:1235–1240.
   PubMed Web of Science ®Google Scholar
• Fisher EJ, Chaloner K, Cohn DL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. Aids. 2001;15:1695–1700.
   PubMed Web of Science ®Google Scholar
• Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in HIV infected patients: three cases of renal failure, fanconi syndrome and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36:1070–1073.
   PubMed Web of Science ®Google Scholar
• Pradat P, Le Pogam MA, Cotte L, et al. Evolution of glomerular filtration rate in HIV-infected, HIV-HBV coninfected and HBV-infected patients receiving tenofovir disoproxil fumarate. J Viral Hepat. 2013;20:650–657.
   PubMed Web of Science ®Google Scholar
• Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2012;35:1317–1325.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Js H, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double blind, randomized, placebo-controlled studies. Kidney Int. 2004;66:1153–1158.
   PubMed Web of Science ®Google Scholar
• Hartono JL, Aung MO, Dan YY, et al. Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2013;37:710–719.
   PubMed Web of Science ®Google Scholar
• Mallet V, Schwarzinger M, Pol S, et al. Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection. Clin Gastroenterol Hepatol. 2015;13:1181–1188.
   PubMed Web of Science ®Google Scholar
• Kearney BP, Liaw S, Yale K, et al. Pharmacokinetics following single dose administration of tenofovir DF in patients with renal impairment. Abstract P4, Sixth International Congress on Drug Therapy in HIV Infection; 2002 Nov 17–21; Glasgow, UK.
   Google Scholar
• Koklu S, Gulsen MT, Tuna Y, et al. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B. Aliment Pharmacol Ther. 2015;41:310–319.
   PubMed Web of Science ®Google Scholar
• Gish R, Mangahas M, Baqai S, et al. Risk of renal toxicity with tenofovir DF for chronic hepatitis B. J. Hepatol. 2010;52:S388–S389.
   Web of Science ®Google Scholar
• Dai CL, Zhu M, Wang BP, et al. Prolonged adefovir therapy associated fanconi syndrome and interstitial nephritis in hepatitis B. Intern Med J. 2012;42:955–957.
   PubMed Web of Science ®Google Scholar
• Lin Q, Pan F, Hong F, et al. Hypophosphatemic osteomalacia and renal fanconi syndrome induced by adefovir in a patient with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi. 2014;22:779–780.
   PubMedGoogle Scholar
• Law S-T, Li KK, Ho YY. Acquired fanconi syndrome associated with prolonged adefovir dipivoxil therapy in a chronic hepatitis B patient. Am J Ther. 2013;20:e713–e716.
   PubMed Web of Science ®Google Scholar
• Li L, Dong GF, Zhang X, et al. Adefovir dipivoxil-induced fanconi syndrome and hypophosphatemic osteomalacia associated with muscular weakness in a patient with chronic hepatitis B. Nan Fang Yi Ke Da Xue Xue Bao. 2011;31:1956–1956.
   PubMedGoogle Scholar
• Gracey DM, Snelling P, McKenzie P, et al. Tenofovir-associated fanconi syndrome in patients with chronic hepatitis B monoinfection. Antivir Ther. 2013;18:945–948.
   PubMed Web of Science ®Google Scholar
• Samarkos M, Theofanis V, Eliadi I, et al. Tenofovir-associated fanconi syndrome in a patient with chronic hepatitis B. J Gastrointestin Liver Dis. 2014;23:342–342.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Park CW, Song MJ. Tenofovir-associated fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection. Hepatology. 2015;62:1318–1320.
   PubMed Web of Science ®Google Scholar
• Vigano M, Brocchieri A, Spinetti A, et al. Tenofovir-induced fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. J Clin Virol. 2014;61:600–603.
   PubMed Web of Science ®Google Scholar
• Magalhaes-Costa P, Matos L, Barreiro P, et al. Fanconi syndrome and chronic renal failure in a chronic hepatitis B monoinfected patient treated with tenofovir. Rev Esp Enferm Dig. 2015;107:512–514.
   PubMed Web of Science ®Google Scholar
• Li X, Zhong C, Yang S, et al. Influence of adefovir dipivoxil or telbivudine monotherapy on renal function of patients with chronic hepatitis B. Nan Fang Yi Ke Da Xue Xue Bao. 2012;32:826–829.
   PubMedGoogle Scholar
• Gane E, Deray G, Liaw YF, et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology. 2014;146:138–146.
   PubMed Web of Science ®Google Scholar
• Lee M, Oh S, Lee HJ, et al. Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. J Viral Hepat. 2014;21:873–881.
   PubMed Web of Science ®Google Scholar
• Qi X, Wang J, Zhang J, et al. Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B. Medicine (Baltimore). 2015;94:e646–646.
   PubMed Web of Science ®Google Scholar
• Qi X, Wang JY, Zhang J, et al. Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China. J Viral Hepat. 2015;22:46–54.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang D. [Influence of monotherapy with telbivudine or entecavir on renal function in patients with chronic hepatitis B]. Zhonghua Gan Zang Bing Za Zhi. 2015;23:407–411.
   PubMedGoogle Scholar
• Perrella A, Lanza AG, Pisaniello D, et al. Telbivudine prophylaxis for hepatitis B virus recurrence after liver transplantation improves renal function. Transplant Proc. 2014;46:2319–2321.
   PubMed Web of Science ®Google Scholar
• Bedimo R, Maalouf N, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. Aids. 2012;26:825–831.
   PubMed Web of Science ®Google Scholar
• Mateo L, Holgado S, Mariñoso ML, Hypophosphatemic osteomalacia induced by tenofovir en HIV-infected patients. Clin Rheumatol. 2014. publihsed online 3 May 2014. DOI:10.1007/s10067-014-2627-x.
   PubMedGoogle Scholar
• Chen YC, Hwang JS, Lin CY, et al. Reduced bone mineral density in patients with non-cirrhotic chronic hepatitis B or C infection. Hepatol Int. 2013;7:S232.
   Google Scholar
• Gill US, Al-Shamma S, Burke K, et al. Factors determining bone mineral density loss in chronic hepatitis B patients: is tenofovir disoproxil fumarate the main culprit? J. Hepatol. 2011;54:S286–S286.
   Google Scholar
• Amini-Bavil-Olyaee S, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology. 2009;49:1158–1165.
   PubMed Web of Science ®Google Scholar
• Kim Du H, Sung DH, Min YK. Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review. J Bone Miner Metab. 2013;31:240–246.
   PubMed Web of Science ®Google Scholar
• Gill US, Zissimopoulos A, Kennedy PT, et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? J Infect Dis. 2015;211:374–382.
   PubMed Web of Science ®Google Scholar
• Wong GL, Choi KK, Chan HL, Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. Hepatology. 2015;62:684–693.
   PubMed Web of Science ®Google Scholar
• Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. J. Hepatol. 2009;50:2001–2006.
   Web of Science ®Google Scholar
• Marzano A, Marengo A, Marietti M, et al. Lactic acidosis during entecavir treatment in decompensated hepatitis B virus-related cirrhosis. Dig Liver Dis. 2011;43:1027–1028.
   PubMedGoogle Scholar
• Mao H, Kang T. Lactic acidosis during entecavir antiviral treatment in a patient with hepatitis B virus-related decompensated cirrhosis. West Indian Med J. 2015;64:165–166.
   PubMed Web of Science ®Google Scholar
• Cohen SM, Levy RM, Jovanovich JF, et al. Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B. J Clin Gastroenterol. 2009;43:1008–1010.
   PubMed Web of Science ®Google Scholar
• McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995;333:1099–1105.
   PubMed Web of Science ®Google Scholar
• Jin JL, Hu P, Lu JH, et al. Lactic acidosis during telbivudine treatment for HBV: A case report and literature review. World J Gastroenterol. 2013;19:5575–5580.
   PubMed Web of Science ®Google Scholar
• Osler M, Stead D, Rebe K, et al. Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study. HIV Med. 2010;11:121–129.
   PubMed Web of Science ®Google Scholar
• Ter Hofstede HJ, De Marie S, Foudraine NA, et al. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS. 2000;11:611–616.
   PubMed Web of Science ®Google Scholar
• Patel V, Hedayati SS. Lactic acidosis in an HIV-infected patient receiving highly active antiretroviral therapy. Nat Clin Pract Nephrol. 2006;2:109–114.
   PubMedGoogle Scholar
• Liu M, Cai H, Yi W. Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. J Viral Hepat. 2013;20(Suppl. 1):65–70.
   PubMed Web of Science ®Google Scholar
• Su GG, Pan KH, Zhao NF, et al. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol. 2004;10:910–912.
   PubMed Web of Science ®Google Scholar
• Reddick KL, Jhaveri R, Gandhi M, et al. Pregnancy outcomes associated with viral hepatitis. J Viral Hepat. 2011;18:e394–e398.
   PubMed Web of Science ®Google Scholar
• Safir A, Levy A, Sikuler E, et al. Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome. Liver Int. 2010;30:765–770.
   PubMed Web of Science ®Google Scholar
• Yi W, Liu M, Cai H-D. Safety of lamivudine treatment for chronic hepatitis B in early pregnancy. World J Gastroenterol. 2012;18:6645–6650.
   PubMed Web of Science ®Google Scholar
• Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J. Hepatol. 2014;61:502–507.
   PubMed Web of Science ®Google Scholar
• Zhang H, Pan CQ, Liu X, et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014;60:468–476.
   PubMed Web of Science ®Google Scholar
• Chen HL, Lee CN, Chang MH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology. 2015;62:375–386.
   PubMed Web of Science ®Google Scholar
• Liu YX, Li J, Xiao J, et al. Efficacy and safety of telbivudine in different trimesters of pregnancy with high viremia for interrupting perinatal transmission of hepatitis B virus. Hepatol Res. 2006. published online 13 Apr 2015 DOI:10.1111/hepr.12525.
   Web of Science ®Google Scholar
• Bae WH, Wester C, Essex M, et al. Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. Aids. 2008;22:1633–1640.
   PubMed Web of Science ®Google Scholar
• Bzowej NH. Hepatitis B therapy in pregnancy. Curr Hepat Rep. 2010;9:197–204.
   PubMedGoogle Scholar
• Borgia G, Carleo MA, Gentile I, et al. Hepatitis B in pregnancy. World J Gastroenterol. 2012;18:4677–4683.
   PubMed Web of Science ®Google Scholar
• Tran TT. Management of hepatitis B in pregnancy: weighing the options. Cleve Clin J Med. 2009;76(Suppl 3):S25–29.
   PubMedGoogle Scholar
• Benaboud S, Provost A, Hirt D, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Côte d’Ivoire, in the ANRS 12109 TEmA A study, step 2. Antimicro Agents Chemother. 2011;55:1315–1317.
   PubMed Web of Science ®Google Scholar
• Gouraud A, Millaret A, Vial T, et al. Tenofovir exposure through breast feeding: serum concentrations in neonates and clinical follow up. Fundam Clin Pharmacol. 2012;26:9.
   Web of Science ®Google Scholar
• Pan CQ, Mi LJ, Reddy KR, et al. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci. 2012;57:2423–2429.
   PubMed Web of Science ®Google Scholar